AKR1B10 and breast carcinoma: The findings raise the opportunity to use AKR1B10 expression to identify breast cancer patients with an increased risk of distant metastatic relapse, and further develop AKR1B1023 and FAO32 inhibitors in the advanced breast cancer setting.